Nomogram to Assess the Survival Benefit of New Salvage Agents for Metastatic Urothelial Carcinoma in the Era of Immunotherapy Article

Sonpavde, Guru, Pond, Gregory Russell, RosenberG, Jonathan E et al. (2018). Nomogram to Assess the Survival Benefit of New Salvage Agents for Metastatic Urothelial Carcinoma in the Era of Immunotherapy . 16(4), E961-E967. 10.1016/j.clgc.2018.03.016

Industry Collaboration International Collaboration

cited authors

  • Sonpavde, Guru; Pond, Gregory Russell; RosenberG, Jonathan E; Choueiri, Toni K; Bellmunt, Joaquim; Regazzi, Ashley Marie; Mullane, Stephanie A; Necchi, Andrea; Raggi, Daniele; Lee, Jae-Lynn; Lee, Soonil; Simpson, Joe; Derleth, Christina Louise; Lin, Shih-Wen; Bajorin, Dean F

sustainable development goals

authors

publication date

  • August 1, 2018

keywords

  • 2ND-LINE TREATMENT
  • Atezolizumab
  • CANCER
  • CHEMOTHERAPY
  • CISPLATIN-INELIGIBLE PATIENTS
  • Immunotherapy
  • Life Sciences & Biomedicine
  • MULTICENTER
  • OPEN-LABEL
  • Oncology
  • PACLITAXEL
  • PHASE-II TRIAL
  • Postplatinum
  • SINGLE GROUP
  • Salvage therapy
  • Science & Technology
  • TRANSITIONAL-CELL CARCINOMA
  • Urology & Nephrology

Digital Object Identifier (DOI)

publisher

  • CIG MEDIA GROUP, LP

start page

  • E961

end page

  • E967

volume

  • 16

issue

  • 4